

Bimekizumab Demonstrates Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies

Martin Rudwaleit,¹ Sofia Ramiro,^{2,3} Denis Poddubnyy,^{4,5} Marina Magrey,⁶ Irene E. van der Horst-Bruinsma,⁷ Atul Deodhar,⁸ Vanessa Taieb,⁹ Diana Voiniciuc,¹⁰ Natasha de Peyrecave,¹¹ Lianne S. Gensler¹²

¹Bielefeld University, Medical School and University Hospital Center OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany; ²Leiden University Medical Center, Department of Rheumatology, Leiden, The Netherlands; ³Zuyderland Medical Center, Heerlen, The Netherlands; ⁴University of Toronto, Division of Rheumatology, Toronto, Ontario, Canada; ⁵Charité – Universitätsmedizin Berlin, Infectious Diseases and Rheumatology, Department of Gastroenterology, Berlin, Germany; ⁶Case Western Reserve University, University Hospitals, Cleveland, Ohio, USA; ⁷Radboud University Medical Centre, Department of Rheumatology, Nijmegen, The Netherlands; ⁸Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Portland, Oregon, USA; ⁹UCB, Colombes, France; ¹⁰UCB, Slough, United Kingdom; ¹¹UCB, Brussels, Belgium; ¹²University of California, San Francisco, Department of Medicine/Rheumatology, San Francisco, California, USA.

Objective

To assess the efficacy of bimekizumab (BKZ) treatment to Week 52 in patients across the full disease spectrum of axial spondyloarthritis (axSpA), focusing on potential sex-based differences in treatment response.

Background

- Female patients with axSpA typically have a higher disease burden and reduced response to treatment compared with male patients.¹
- BKZ, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated sustained efficacy to Week 52 in patients with non-radiographic (nr-) and radiographic (r-) axSpA in the phase 3 studies BE MOBILE 1 and 2.^{2,3}
- Here, we present BKZ efficacy in male vs female patients with axSpA, up to Week 52 in BE MOBILE 1 and 2.

Methods

- In BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743), patients were randomized to subcutaneous BKZ 160 mg every 4 weeks (Q4W) or placebo for Weeks 0–16 (double-blind period); all received BKZ in Weeks 16–52 (maintenance period).
- We report a post-hoc analysis of the following efficacy outcomes to Week 52, stratified by sex: ASAS40 responders (non-responder imputation [NRI]), patients achieving ASDAS <2.1 (multiple imputation [MI]) and mean absolute BASDAI score (MI), mean absolute values for MRI SPARCC SJI score, MRI Berlin spine score and hs-CRP (observed case [OC]); mean CIB in ASQoL score (MI).
- Since all analyses were post-hoc, no formal p values were provided.
- To compare efficacy in male vs female patients for binary outcomes, adjusted relative odds ratios (rOR) and odds ratios (OR) are reported at Week 16 and Week 52, respectively.
- For most continuous outcomes, adjusted relative differences and differences are reported at Week 16 and Week 52, respectively. Due to skewed distribution, adjusted relative ratio to baseline and ratio to baseline, at Week 16 and Week 52, respectively, are reported for hs-CRP.

Results

Baseline characteristics

- 254 patients (male: 138/254; female: 116/254) with nr-axSpA were randomized in BE MOBILE 1 and 332 patients (male: 240/332; female: 92/332) with r-axSpA were randomized in BE MOBILE 2.
- Of these, 220/254 (male: 124/138 [89.9%]; female: 96/116 [82.8%]) and 298/332 (male: 215/240 [89.6%]; female: 83/92 [90.2%]) completed Week 52.
- Key baseline differences between male and female patients included longer mean symptom duration (years), lower HLA-B27 positivity (%), and worse health-related quality of life (HRQoL), according to higher mean ASQoL scores in females (Table 1). Mean baseline BASDAI and objective signs of inflammation (OSI) scores are shown in Figures 1–2.

Disease activity

- Across ASAS40, ASDAS <2.1, and BASDAI, there was a pattern of higher BKZ vs placebo treatment effect in male vs female patients at Week 16, which was reflected in the rORs and RDs at this timepoint (Figure 1).
- At Week 52, treatment responses were higher in males vs females with nr-axSpA but comparable in patients with r-axSpA, which was reflected in the ORs and differences at this timepoint.
- Overall, at Week 52 both males and females responded well in both trials, with >50% of BKZ-randomized patients achieving ASAS40, >40% achieving ASDAS <2.1, and with good overall response in mean improvements in BASDAI scores (Figure 1).

Objective signs of inflammation

- For CIB in OSI outcomes, relative differences generally indicated a higher BKZ vs placebo treatment effect in males vs females at Week 16; however, absolute OSI values in males and females at this timepoint were mostly comparable, despite males generally having higher OSI scores at baseline (Figure 2). The number of female patients with MRI scores in the r-axSpA placebo group was limited.
- At Week 52, improvements in MRI SPARCC SJI and MRI Berlin spine scores were comparable between male vs female patients with nr-axSpA or r-axSpA, as reflected in the difference values for CIB at this timepoint.
- The ratio to baseline for hs-CRP at Week 52 indicated a higher BKZ effect in males vs females in nr-axSpA, but not in r-axSpA (Figure 2).

Health-related quality of life

- Both male and female patients reported substantial improvements (mean CIB) in ASQoL at Week 16 with BKZ treatment (nr-axSpA: -5.5 vs -4.8, r-axSpA: -4.8 vs -5.5) compared with placebo (nr-axSpA: -2.1 vs -2.9; r-axSpA: -3.1 vs -3.7).
- Improvements continued to Week 52 with BKZ (nr-axSpA: continuous BKZ: -5.7 vs -6.2, placebo/BKZ-switchers: -5.5 vs -5.1; r-axSpA: continuous BKZ: -5.4 vs -6.5, placebo/BKZ-switchers: -5.5 vs -5.8).

Conclusions


In this first analysis comparing efficacy outcomes between sexes in BE MOBILE 1 and 2, the treatment effect of bimekizumab vs placebo at Week 16 tended to be higher among male patients with axSpA compared with their female counterparts, including MRI outcomes (despite higher baseline scores in males vs females).

However, by Week 52, female patients showed improvement in longer-term treatment response to BKZ, with efficacy approaching similar levels to those seen in male patients at this timepoint.

Overall, the efficacy of BKZ for disease activity, OSI, and HRQoL outcomes was demonstrated in both male and female patients across the full disease spectrum of axSpA.

Summary

We assessed the efficacy of bimekizumab treatment to Week 52 in male vs female patients



Overall, the efficacy of bimekizumab for disease activity, objective signs of inflammation and HRQoL outcomes was demonstrated in both male and female patients across the full disease spectrum of axSpA

Table 1 Baseline characteristics in BE MOBILE 1 (nr-axSpA) and BE MOBILE 2 (r-axSpA), stratified by sex



	BE MOBILE 1 (nr-axSpA)		BE MOBILE 2 (r-axSpA)	
	Male	Female	Male	Female
Age, years, mean ± SD	36.4 ± 10.6	37.8 ± 10.5	42.7 ± 12.3	41.6 ± 11.6
Symptom duration, years, mean ± SD	6.9 ± 7.3	7.6 ± 7.5	11.2 ± 10.0	11.1 ± 9.9
Time since diagnosis, years, mean ± SD	3.4 ± 5.7	3.3 ± 5.9	3.7 ± 5.0	4.1 ± 6.6
TNFI naïve, n (%)	57 (87.7)	69 (94.5)	52 (85.2)	49 (89.1)
HLA-B27 positive, n (%)	58 (89.2)	59 (80.8)	36 (59.0)	44 (80.0)
ASDAS, mean ± SD	3.7 ± 0.8	3.6 ± 0.8	3.7 ± 0.7	3.9 ± 0.7
ASQoL, mean ± SE	8.6 ± 0.6	8.5 ± 0.5	10.2 ± 0.5	10.8 ± 0.6
hs-CRP >ULN, n (%)	39 (60.0)	37 (50.7)	32 (52.5)	33 (60.0)

Randomized set. [a] ULN value for hs-CRP is 5 mg/L.

ANCOVA: analysis of covariance; ASAS40: Assessment in SpondyloArthritis International Society 40% improvement; ASDAS: axial spondyloarthritis disease activity score; ASQoL: Ankylosing Spondylitis Quality of Life Questionnaire; axSpA: axial spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BKZ: bimekizumab; CIB: change from baseline; CI: confidence interval; HLA-B27: human leukocyte antigen B27; HRQoL: health-related quality of life; hs-CRP: high-sensitivity C-reactive protein; IL: interleukin; MI: multiple imputation; MRI: magnetic resonance imaging; nr-axSpA: non-radiographic axial spondyloarthritis; NRI: non-responder imputation; OC: observed case; OR: odds ratio; OSI: objective signs of inflammation; PBO: placebo; Q4W: every 4 weeks; r-axSpA: radiographic axial spondyloarthritis; RD: relative difference; rOR: relative odds ratio; SD: standard deviation; SE: standard error; SJI: sacroiliac joint; SPARCC: Spondyloarthritis Research Consortium of Canada; TNFI: tumor necrosis factor inhibitor; ULN: upper limit of normal.



References: van der Horst-Bruinsma I. Ann Rheum Dis 2013;72:1221–4; van der Heijde D. Ann Rheum Dis 2023;82:515–26; Baraliakos X. Ann Rheum Dis 2024;83:199–213. **Author Contributions:** Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: MR, SR, DP, MM, IvdHB, AD, VT, DV, NdP, LSG. Drafting of the publication, or reviewing it critically for important intellectual content: MR, SR, DP, MM, IvdHB, AD, VT, DV, NdP, LSG. Final approval of the publication: MR, SR, DP, MM, IvdHB, AD, VT, DV, NdP, LSG. **Disclosures:** MR: Speakers bureau from AbbVie, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB; consultant for AbbVie, Eli Lilly and Company, Janssen, Novartis, Pfizer, Takeda, and UCB; grants from AbbVie, Aifasigma, Eli Lilly and Company, MSD, Novartis, Pfizer, and UCB. DP: Speaker for AbbVie, BMS, Eli Lilly and Company, Gilead, GSK, MoonLake, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB; grant/research support from AbbVie, Eli Lilly and Company, MSD, Novartis, Pfizer, and UCB. MM: Consultancy fees from AbbVie, BMS, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB. IvdHB: Consultant for AbbVie, Eli Lilly and Company, MSD, Novartis, and UCB; unrestricted grants received for investigator-initiated studies from AbbVie, BMS, MSD, and Pfizer. AD: Speaker for Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB. VT: Speaker for Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB. DV: Former contractor for UCB and employee of Veramed. NdP: Employee of UCB. LSG: Grants from UCB paid to institution; consulting fees from Acelyn, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB. **Acknowledgments:** We would like to thank the patients and their caregivers in addition to all the investigators and their teams who contributed to this study. The authors acknowledge Celia Menckberg, PhD, UCB, Breda, the Netherlands, for publication coordination, Georgina Gregory, PhD, Costello Medical, Manchester, UK for medical writing and editorial assistance, and the Costello Medical Creative team for design support. Funded by UCB. All costs associated with development of this presentation were funded by UCB.

Figure 1 Disease activity outcomes to Week 52, stratified by sex



Randomized set. rOR and RD for the comparison of BKZ vs PBO treatment effect in males vs females at Week 16 were calculated using logistic regression and ANCOVA, respectively. OR and difference for the comparison of males vs females in BKZ-randomized patients at Week 52 were calculated using logistic regression and ANCOVA, respectively. All rOR/OR and RD/difference analyses were adjusted for region, baseline age, HLA-B27 status and, for the continuous endpoints, their baseline values. Additionally, in patients with nr-axSpA, rOR/OR and RD/difference analyses were adjusted for MRI/CRP classification and, in patients with r-axSpA, for prior TNFI exposure and baseline hs-CRP.

Figure 2 Objective signs of inflammation outcomes to Week 52, stratified by sex



Randomized set. RD for the comparison of BKZ vs PBO treatment effect in males vs females at Week 16 was calculated using ANCOVA. Difference for the comparison of males vs females in BKZ-randomized patients at Week 52 was calculated using ANCOVA. All RD/difference analyses were adjusted for region, baseline age, HLA-B27 status, and MRI baseline values. Additionally, in patients with nr-axSpA, RD/difference analyses were adjusted for MRI/CRP classification and, in patients with r-axSpA, for prior TNFI exposure and baseline hs-CRP. For MRI outcomes, only study participants enrolled in the MRI sub-studies are included. Due to skewed distribution, hs-CRP data are presented in panel C using median of absolute values to Week 52, and ratio to baseline values of the geometric mean were used for ANCOVA relative ratio analyses, shown in panel D.

To receive a copy of this poster, scan the QR code.

Link expiration: February 22, 2026

